Two-year-old Drugcendr Inc. became the latest biopharma to take a stab at pancreatic cancer by advancing lead compound, CEND-1, into a phase I trial in individuals with metastatic pancreatic ductal adenocarcinoma (PDAC) undergoing combination therapy with Abraxane (nab-paclitaxel, Celgene Corp.) and gemcitabine.